Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 3Phase 3 1Phase 1/2 1

Status

Recruiting 5Completed 2

Sponsor Class

OTHER 4NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × talazoparib × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05873192 2026-05-05

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06844383 2026-04-24

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting
126 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

Phase 2 Recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

NCT04332744 2025-05-11

ZZ-First

MedSIR

Phase 2 Completed
54 enrolled
Genitourinary

Prostatic Neoplasms

NCT06582628 2024-12-02

TEAM PC

Fundacion Oncosur

Phase 2 Recruiting
78 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms

NCT03148795 2024-04-05

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Pfizer

Phase 2 Completed
128 enrolled 25 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡